Press coverage about CombiMatrix Corporation (NASDAQ:CBMX) has been trending somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CombiMatrix Corporation earned a news impact score of 0.07 on Accern’s scale. Accern also gave media coverage about the medical research company an impact score of 44.7302319831252 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

A number of research firms have weighed in on CBMX. Ladenburg Thalmann Financial Services lowered shares of CombiMatrix Corporation from a “buy” rating to a “neutral” rating in a research note on Friday, August 4th. Aegis began coverage on shares of CombiMatrix Corporation in a research note on Thursday, July 13th. They set a “buy” rating and a $8.10 price objective for the company.

CombiMatrix Corporation (NASDAQ:CBMX) traded down 1.27% during mid-day trading on Friday, reaching $7.80. 37,017 shares of the company’s stock were exchanged. The firm’s market capitalization is $22.76 million. The company’s 50-day moving average is $7.52 and its 200 day moving average is $6.01. CombiMatrix Corporation has a one year low of $2.15 and a one year high of $8.05.

CombiMatrix Corporation (NASDAQ:CBMX) last posted its quarterly earnings data on Thursday, August 3rd. The medical research company reported ($0.13) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.11. CombiMatrix Corporation had a negative net margin of 15.53% and a negative return on equity of 36.07%. The firm had revenue of $4.24 million for the quarter, compared to the consensus estimate of $3.89 million. Equities analysts predict that CombiMatrix Corporation will post ($0.52) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “CombiMatrix Corporation (CBMX) Getting Somewhat Favorable News Coverage, Study Shows” was originally published by Watch List News and is the property of of Watch List News. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.watchlistnews.com/combimatrix-corporation-cbmx-getting-somewhat-favorable-news-coverage-study-shows/1617566.html.

CombiMatrix Corporation Company Profile

CombiMatrix Corporation is a provider of molecular diagnostic solutions. The Company specializes in pre-implantation genetic screening, miscarriage analysis, prenatal diagnosis and pediatric developmental disorders, offering deoxyribonucleic acid-based testing for the detection of genetic abnormalities, which cannot be identified through traditional methodologies.

Insider Buying and Selling by Quarter for CombiMatrix Corporation (NASDAQ:CBMX)

Receive News & Ratings for CombiMatrix Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CombiMatrix Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.